Cambodia Pharmaceuticals and Healthcare Report Q2 2012

Date: April 17, 2012
Pages: 55
US$ 1,295.00
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Download

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: The Association of Southeast Asia Nations (ASEAN) is becoming increasingly attractive to foreign investors given the association’s plans to boost economic development through the ASEAN Economic Community (AEC) by 2015. Despite this we highlight that major improvements have to be made in Cambodia’s regulatory processes, the government’s commitment to healthcare and lowering corruption to attract foreign pharmaceutical and healthcare companies.

Headline Expenditure Projections
  • Pharmaceuticals: CHR877bn (US$217mn) in 2011 to CHR984bn (US$236mn) in 2012; +12.3% in local currency terms and +8.9% in US dollar terms.
  • Healthcare: CHR2,982bn (US$737mn) in 2011 to CHR3,312bn (US$794mn) in 2012; +11.0% in local currency terms and +57.8% in US dollar terms.
  • Medical devices: CHR108bn (US$27mn) in 2011 to CHR118bn (US$28mn) in 2011; +9.8% in local currency terms and +6.5% in US dollar terms.
Risk/Reward Rating:

In Q212, Cambodia continues to rank last out of the 18 key markets in our Asia Pacific Risk/Reward Ratings (RRRs), with a low score of 33.5. Given the country’s poor governance and high level of corruption, it will remain low on investors’ priorities until there are improvements to its overall economic conditions.

Key Trends And Developments
  • In February 2012, Germany-based Merck KGaA said its business in South East Asia will be facilitated by the AEC, which aims to promote economic development throughout ASEAN. In relation to Cambodia, the company said unmet medical needs offer great opportunities for its products.
  • In January 2012, the Ministry of Health reported that at least 72 children had due to dengue fever in Cambodia in 2011, an increase of 89% year-on-year (y-o-y), compared with 38 deaths reported in 2010. The ministry said the incidence of dengue fever rose by 26% y-o-y to 15,805 cases in 2011. Ngan Chantha, the director of dengue control at the Ministry of Health, said the incidence of the disease rose and deaths increased due to a large breakout. Chantha attributed the rise to the severe floods that submerged most provinces in August-October 2011. He estimated Cambodia spent US$7mn to counter the outbreak of the disease and provide medical attention.
BMI Economic View:

Despite a slight uptick in the y-o-y rate of the consumer price index (CPI), to 5.6% in November 2011 from 5.3% in the previous month, we maintain our view that inflationary pressure in Cambodia will continue to cool in 2012. On a month-on-month (m-o-m) basis, headline CPI actually contracted in November (by 0.7%) for the first time since December 2010, led by a 1.3% m-o-m decline in food prices. Our view of steady or lower global food prices in the months ahead should help take the sting out of price pressure and, as such, we maintain our forecast of 3.0% average CPI in 2012.

BMI Political View:

Continued cooperation between the Cambodian and Vietnamese governments regarding border delineation should help to boost bilateral economic cooperation between the countries. The improvement in border cooperation with Vietnam over recent years helps Cambodia score a relatively solid 70 out of 100 in the securities/external threat component of our short-term political risk ratings, though the unresolved border dispute with Thailand continues to be a drag on its overall score.
Executive Summary
SWOT Analysis
Cambodia Pharmaceuticals And Healthcare Industry SWOT
Pharmaceutical Risk/Reward Ratings
  Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q212
Cambodia – Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Medicines
Pricing And Reimbursement
Industry Trends And Developments
Healthcare Sector
Health Insurance
Research & Development Sector
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
  Table: Pharmaceutical Sales, 2008-2016
Key Growth Factors – Industry
  Table: Overall Healthcare Expenditure, 2008-2016
  Table: Government Healthcare Expenditure, 2008-2016
  Table: Private Healthcare Expenditure, 2008-2016
Key Growth Drivers – Macroeconomic
  Table: Cambodia Economic Activity, 2011-2016
Medical Device Market Forecast
  Table: Medical Devices Sales, 2008-2016
Pharmaceutical Trade Forecast
  Table: Pharmaceutical Trade, 2008-2016
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Pharmaceutical Company Developments
Pharmaceutical Wholesale
Pharmaceutical Retail
Company Profiles
Local Companies
PharmaProduct Manufacturing
Cambodia Pharmaceutical Enterprise
Multinational Companies
Country Snapshot: Cambodia Demographic Data
Section 1: Population
  Table: Demographic Indicators, 2005-2030
  Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
  Table: Education, 2002-2005
  Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
  Table: Employment Indicators, 2000-2004
  Table: Consumer Expenditure, 2000-2009 (US$mn)
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceutical Business Environment Indicators
  Table: Weighting Of Components
Skip to top

Cambodia Pharmaceuticals and Healthcare Report Q3 2012 US$ 1,295.00 Aug, 2012 · 56 pages
Cambodia Pharmaceuticals and Healthcare Report Q4 2012 US$ 1,295.00 Oct, 2012 · 57 pages
Pakistan Pharmaceuticals and Healthcare Report Q1 2016 US$ 1,295.00 Nov, 2015 · 106 pages
Hungary Pharmaceuticals and Healthcare Report Q4 2015 US$ 1,295.00 Aug, 2015 · 110 pages

Ask Your Question

Cambodia Pharmaceuticals and Healthcare Report Q2 2012
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: